← Leaderboards
Brian Michael Luna
University Of Southern California
$3,067,362
Attributed
$3,067,362
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $696.6K · FY2018–24$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$3,067,362 · 2
By mechanism
R01$3,067,362 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Southern California
Same institution · by research overlap
- Roger W. Jelliffe$6,383,465
- Justin Blaine Schaal$3,025,760
- Timothy C Fisher$1,699,812
- Feixue Fu$3,534,516
Others in their field
Other Emerging Leaders on “Sepsis”
- Bobby Reddy · Prenosis, Inc.$8,396,645
- Matthew R Vogt · Univ Of North Carolina Chapel Hill$7,950,648
- Nadir Yehya · Children'S Hosp Of Philadelphia$7,358,577
- Mayur B Patel · Vanderbilt University Medical Center$6,650,432
- Md, Kanecia Zimmerman · Duke University$5,999,956
- Terry Roemer · Prokaryotics, Inc.$5,560,006
Research focus
SepsisIn VivoIn VitroRifabutinClinical TrialsCellsFda ApprovedInfectionLung InfectionsRandomized Controlled Clinical TrialsTranslationsTrendPredispositionMouse ModelAntibiotic ResistanceAcinetobacter BaumanniiAntibioticsColistinAnti-Bacterial AgentsBacterial Antibiotic ResistanceDrug ResistanceBacteriaBacteremiaEnvironment
Grant awards (7)
Identifying Synergistic Rifabutin-Containing Combinations Against A. baumannii$688,572
R01 · FY2024 · AI · contact PI
Characterization of Rifabutin Therapy Against Antibiotic-Resistant Bacteria$557,606
R01 · FY2021 · AI · contact PI
Characterization of Rifabutin Therapy Against Antibiotic-Resistant Bacteria$69,506
R01 · FY2021 · AI · contact PI
Characterization of Rifabutin Therapy Against Antibiotic-Resistant Bacteria$69,506
R01 · FY2021 · AI · contact PI
Characterization of Rifabutin Therapy Against Antibiotic-Resistant Bacteria$558,043
R01 · FY2020 · AI · contact PI
Characterization of Rifabutin Therapy Against Antibiotic-Resistant Bacteria$566,294
R01 · FY2019 · AI · contact PI
Characterization of Rifabutin Therapy Against Antibiotic-Resistant Bacteria$557,835
R01 · FY2018 · AI · contact PI